ESSA Pharma/EPIX
$6.25
0.8%-
1D1W1MYTD1YMAX
About ESSA Pharma
ESSA Pharma Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is focused on developing proprietary therapies for the treatment of patients with prostate cancer. Its lead candidate, EPI-7386, is an oral, small molecule that inhibits the N-terminal domain of the androgen receptor (AR). The Company is completing the initial Phase I clinical development of EPI-7386 as a monotherapy treatment for patients with metastatic castration-resistant prostate cancer (mCRPC). The Company is also developing ANITen bAsed Chimera (ANITAC) AR NTD degraders to suppress androgen biology.
Ticker
EPIX
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology & Drugs
CEO
David Parkinson
Employees
50
Headquarters
Vancouver, Canada
Website
www.essapharma.com
ESSA Pharma Metrics
BasicAdvanced
$265M
Market cap
-
P/E ratio
-$0.59
EPS
1.81
Beta
-
Dividend rate
Price and volume
Market cap
$265M
Beta
1.80523
52-week high
$11.67
52-week low
$2.58
Average daily volume
72K
Financial strength
Current ratio
40.746
Management effectiveness
Return on assets (TTM)
-16.68%
Return on equity (TTM)
-17.05%
Return on investment (TTM)
-17.03%
Valuation
Price to book
1.884
Price to tangible book (TTM)
1.887
Growth
Earnings per share change (TTM)
21.28%
What the Analysts think about ESSA Pharma
Analyst Ratings
Majority rating from 5 analysts.
Price Targets
Average projection from 5 analysts.
High $29.00
Low $15.00
$6.25
Current price
$19.00
Average price target
ESSA Pharma Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$5.9M
9.26%
Profit margin
0%
NaN%
ESSA Pharma Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.16
-$0.17
-$0.12
-$0.14
-
Expected
-$0.21
-$0.20
-$0.21
-$0.17
-$0.19
Surprise
-21.95%
-12.82%
-42.86%
-18.84%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Upcoming events
FAQs
What’s the current market cap for ESSA Pharma stock?
ESSA Pharma (EPIX) has a market cap of $265M as of May 17, 2024.
What is the P/E ratio for ESSA Pharma stock?
The price to earnings (P/E) ratio for ESSA Pharma (EPIX) stock is 0 as of May 17, 2024.
Does ESSA Pharma stock pay dividends?
No, ESSA Pharma (EPIX) stock does not pay dividends to its shareholders as of May 17, 2024.
When is the next ESSA Pharma dividend payment date?
ESSA Pharma (EPIX) stock does not pay dividends to its shareholders.
What is the beta indicator for ESSA Pharma?
ESSA Pharma (EPIX) has a beta rating of 1.81. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
What is the ESSA Pharma stock price target?
The target price for ESSA Pharma (EPIX) stock is $19, which is 204% above the current price of $6.25. This is an average based on projections from 5 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.
Buy or sell ESSA Pharma stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.